ChartMill assigns a Buy % Consensus number of 43% to HGEN. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-04-03 | Credit Suisse | Reiterate | Underperform |
| 2023-01-11 | Cantor Fitzgerald | Reiterate | Neutral |
| 2022-07-13 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2022-07-13 | Roth Capital | Downgrade | Buy -> Neutral |
| 2022-07-13 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2021-09-10 | Jefferies | Downgrade | Buy -> Hold |
| 2021-09-09 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2021-09-09 | HC Wainwright & Co. | Maintains | Buy |
| 2021-08-13 | Credit Suisse | Maintains | Outperform |
| 2021-08-10 | Roth Capital | Maintains | Buy |
| 2021-06-11 | Credit Suisse | Initiate | Outperform |
| 2021-05-07 | Oppenheimer | Initiate | Outperform |
| 2021-04-12 | HC Wainwright & Co. | Reiterate | Buy |
6 analysts have analysed HGEN and the average price target is 0.15 USD. This implies a price increase of 323.82% is expected in the next year compared to the current price of 0.0361.
The consensus rating for HUMANIGEN INC (HGEN) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
The number of analysts covering HUMANIGEN INC (HGEN) is 6.